In a significant development for the management of achondroplasia—the most prevalent form of human dwarfism—the phase III PROPEL 3 clinical trial has yielded promising results for a novel once-daily oral therapy. The study, published in the New England Journal of Medicine and presented at the International Conference on Children’s Bone Health in Montreal, suggests that infigratinib, an FGFR1-3 tyrosine kinase inhibitor, could offer a potent and more convenient alternative to existing treatments for children living with this skeletal condition.
The findings indicate that infigratinib successfully promotes bone growth by directly targeting the underlying genetic mechanism of the disorder. By providing an oral administration route, this therapy addresses one of the primary logistical challenges associated with current standards of care, which rely on daily injections.
The Core Data: Quantifying Growth Velocity
The PROPEL 3 trial was designed as a randomized, double-blind study to evaluate the efficacy and safety of oral infigratinib compared to a placebo. The primary endpoint was the change from baseline in annualized height velocity (AHV) at 52 weeks.
Key Clinical Metrics
The data revealed a statistically significant advantage for those treated with infigratinib:
- Annualized Height Velocity: Participants in the infigratinib group showed a mean increase of 1.58 cm/year from baseline, compared to a slight decrease of -0.16 cm/year in the placebo group. This resulted in a robust between-group difference of 1.74 cm/year (95% CI 1.31-2.17).
- Height Z-Score Improvement: The study also tracked the achondroplasia-specific height z score—a standardized measure of how a child’s height compares to others with the same condition. The difference in the least-squares mean change between the infigratinib group and the placebo group was 0.32 (96% CI 0.23-0.41), indicating a meaningful improvement in growth trajectory.
- Body Proportions: While researchers noted a trend toward a decrease in the upper-to-lower body segment ratio, the result did not reach statistical significance (least-squares mean change -0.02).
Lead researcher Ravi Savarirayan, MBBS, MD, of the Royal Children’s Hospital in Parkville, Australia, noted that the treatment effect appeared consistent across all measured subgroups. However, the benefits were particularly pronounced in children aged 3 to 7 years—a critical developmental window—and in children at Tanner stage 1 (pre-puberty).
Understanding the Pathogenesis: Why FGFR3 Matters
Achondroplasia is caused by a gain-of-function mutation in the FGFR3 gene. In a healthy individual, fibroblast growth factor receptor 3 (FGFR3) acts as a "brake" on bone growth. In patients with achondroplasia, the mutated receptor is constitutively overactive, constantly signaling the body to stop bone lengthening.
This overactivity triggers downstream cellular pathways, most notably the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 1 (STAT1) pathways, which ultimately impair endochondral ossification—the process by which cartilage is converted into bone.
The Mechanism of Action: A Differentiated Approach
Current FDA-approved therapies, such as vosoritide (Voxzogo) and navepegritide (Yuviwel), function as C-type natriuretic peptide (CNP) analogues. These drugs work by down-regulating FGFR3 signaling primarily through the MAPK pathway.
Infigratinib offers a distinct approach. By binding directly to the FGFR3 receptor, it inhibits the receptor’s phosphorylation, thereby silencing all downstream signaling pathways involved in bone growth retardation. Researchers believe this broad-spectrum inhibition might provide a therapeutic edge, effectively tackling the disorder at the root of the signaling cascade.
Chronology of the PROPEL Clinical Program
The success of PROPEL 3 is the result of years of rigorous scientific investigation and clinical observation.
- Observational Foundations (2019–2023): The PROPEL program began with an observational study (NCT04035811), which tracked children with achondroplasia to establish baseline growth patterns and clinical needs. This study screened 114 participants for the subsequent intervention trials.
- Trial Initiation (Late 2023): Between November 2023 and December 2024, the phase III trial officially launched across 27 sites in 10 countries. The trial recruited children between 3 and 17 years old with a genetically confirmed diagnosis.
- Data Collection and Analysis (2025): The double-blind, randomized (2:1) study followed 75 children receiving the active drug and 39 receiving a placebo.
- Presentation and Publication (2026): With the 52-week data finalized, the results were simultaneously shared with the global medical community via the New England Journal of Medicine and the International Conference on Children’s Bone Health.
Safety Profile and Tolerability
A critical consideration in pediatric drug development is the long-term safety and side-effect profile of chronic medication. According to the PROPEL 3 investigators, infigratinib was generally well-tolerated.
- Adverse Events: Most reported side effects were mild to moderate in severity. The most frequently observed events (occurring in ≥10% of the infigratinib cohort) included common pediatric illnesses such as upper respiratory tract infections, vomiting, pyrexia (fever), cough, headache, and otitis media (ear infections).
- Clinical Laboratory Markers: While three cases of transiently increased serum phosphate levels were observed, they were deemed clinically insignificant and asymptomatic.
- Absence of Major Complications: Notably, there were no reported deaths or adverse events that necessitated the discontinuation of the drug. Furthermore, researchers found no evidence of accelerated bone age progression or adverse changes in bone mineral density, providing reassurance regarding the drug’s long-term safety profile for developing skeletons.
Implications for Clinical Practice
The shift toward an oral medication represents a potential paradigm shift in the treatment of skeletal dysplasias.
Improving Quality of Life
For children with achondroplasia, the burden of daily injections can be significant, impacting both the child’s comfort and the family’s daily routine. An oral formulation—administered as a sprinkle capsule—eliminates the need for needles, potentially improving patient compliance and reducing the psychological stress associated with chronic injectable therapy.
Addressing the Therapeutic Gap
While existing CNP analogues have demonstrated success in increasing height velocity, the clinical community remains interested in therapies that might offer different or additive benefits. By addressing multiple pathways simultaneously, infigratinib could potentially yield more comprehensive skeletal improvements.
Limitations and Future Directions
Despite the positive results, the researchers acknowledged that the 52-week duration is relatively short. Questions remain regarding the impact of the drug on:
- Final adult height.
- Long-term functionality and reduction of medical complications associated with achondroplasia (such as spinal stenosis or sleep apnea).
- Overall health-related quality of life.
To answer these questions, the scientific community is looking toward the ongoing PROPEL OLE (Open-Label Extension) study (NCT05145010). Furthermore, the PROPEL Infant and Toddler trial (NCT07169279) is currently investigating the safety and efficacy of the drug in children under three years of age, potentially opening the door for early intervention at an age where skeletal changes are most malleable.
Conclusion
The PROPEL 3 study marks a significant milestone in pediatric endocrinology and orthopedics. By offering a novel, targeted, and orally administered treatment, infigratinib stands to become a cornerstone in the management of achondroplasia. As long-term data continue to emerge, clinicians and families have reason to be optimistic about a future where the physical challenges of achondroplasia can be more effectively managed, allowing children to reach their full growth potential with greater ease and confidence.
